|
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer. Bevacizumab (bev), when added to a moderate dose combination of previously failed cytotoxins, as a third- and fourth-line therapy for refractory gastric, cholangiocarcinoma, and ovarian cancers, produced high-quality responses. The regimen was based on preclinical models designed in order to simultaneously partner both bev and each of the cytotoxins with 4-5 synergistic drugs. |
|
To evaluate how cine phase-contrast (PC) flow data correlate with the severity of peripheral vascular disease (PVD). |